These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34231329)

  • 1. MTHFD2 promotes ovarian cancer growth and metastasis via activation of the STAT3 signaling pathway.
    Li Q; Yang F; Shi X; Bian S; Shen F; Wu Y; Zhu C; Fu F; Wang J; Zhou J; Chen Y
    FEBS Open Bio; 2021 Oct; 11(10):2845-2857. PubMed ID: 34231329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of MTHFD2 is associated with clinicopathological characteristics and poor survival in ovarian cancer, possibly by regulating MOB1A signaling.
    Cui X; Su H; Yang J; Wu X; Huo K; Jing X; Zhang S
    J Ovarian Res; 2022 Feb; 15(1):23. PubMed ID: 35135596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interference with MTHFD2 induces ferroptosis in ovarian cancer cells through ERK signaling to suppress tumor malignant progression.
    Mo X; Liu Q; Liang K; Song Y
    J Bioenerg Biomembr; 2024 Jun; 56(3):333-345. PubMed ID: 38488992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of MTHFD2 inhibits NSCLC progression by suppressing cycle-related genes.
    Yu C; Yang L; Cai M; Zhou F; Xiao S; Li Y; Wan T; Cheng D; Wang L; Zhao C; Huang X
    J Cell Mol Med; 2020 Jan; 24(2):1568-1577. PubMed ID: 31778025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MTHFD2 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating AKT/GSK-3β/β-catenin signalling.
    Shi Y; Xu Y; Yao J; Yan C; Su H; Zhang X; Chen E; Ying K
    J Cell Mol Med; 2021 Jul; 25(14):7013-7027. PubMed ID: 34121323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion.
    Lin H; Huang B; Wang H; Liu X; Hong Y; Qiu S; Zheng J
    Cell Physiol Biochem; 2018; 51(2):991-1000. PubMed ID: 30466107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage.
    Li G; Wu J; Li L; Jiang P
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34244426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-metabolic function of MTHFD2 activates CDK2 in bladder cancer.
    Liu X; Liu S; Piao C; Zhang Z; Zhang X; Jiang Y; Kong C
    Cancer Sci; 2021 Dec; 112(12):4909-4919. PubMed ID: 34632667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATF4/MYC Regulates MTHFD2 to Promote NSCLC Progression by Mediating Redox Homeostasis.
    Gao Y; Feng L; Zhang L; Geng J; Zhang E
    Dis Markers; 2022; 2022():7527996. PubMed ID: 36051358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion.
    Lehtinen L; Ketola K; Mäkelä R; Mpindi JP; Viitala M; Kallioniemi O; Iljin K
    Oncotarget; 2013 Jan; 4(1):48-63. PubMed ID: 23295955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2.
    Nishimura T; Nakata A; Chen X; Nishi K; Meguro-Horike M; Sasaki S; Kita K; Horike SI; Saitoh K; Kato K; Igarashi K; Murayama T; Kohno S; Takahashi C; Mukaida N; Yano S; Soga T; Tojo A; Gotoh N
    Oncogene; 2019 Apr; 38(14):2464-2481. PubMed ID: 30532069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer.
    Achreja A; Yu T; Mittal A; Choppara S; Animasahun O; Nenwani M; Wuchu F; Meurs N; Mohan A; Jeon JH; Sarangi I; Jayaraman A; Owen S; Kulkarni R; Cusato M; Weinberg F; Kweon HK; Subramanian C; Wicha MS; Merajver SD; Nagrath S; Cho KR; DiFeo A; Lu X; Nagrath D
    Nat Metab; 2022 Sep; 4(9):1119-1137. PubMed ID: 36131208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications.
    Ju HQ; Lu YX; Chen DL; Zuo ZX; Liu ZX; Wu QN; Mo HY; Wang ZX; Wang DS; Pu HY; Zeng ZL; Li B; Xie D; Huang P; Hung MC; Chiao PJ; Xu RH
    J Natl Cancer Inst; 2019 Jun; 111(6):584-596. PubMed ID: 30534944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-33a-5p suppresses colorectal cancer cell growth by inhibiting MTHFD2.
    Yan Y; Zhang D; Lei T; Zhao C; Han J; Cui J; Wang Y
    Clin Exp Pharmacol Physiol; 2019 Oct; 46(10):928-936. PubMed ID: 31209892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial targeting of MTHFD2 and PAICS in purine synthesis as a novel therapeutic strategy.
    Cheung CHY; Hsu CL; Tsuei CY; Kuo TT; Huang CT; Hsu WM; Chung YH; Wu HY; Hsu CC; Huang HC; Juan HF
    Cell Death Dis; 2019 Oct; 10(11):786. PubMed ID: 31624245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTHFD2-mediated redox homeostasis promotes gastric cancer progression under hypoxic conditions.
    Mo HY; Wang RB; Ma MY; Zhang Y; Li XY; Wen WR; Han Y; Tian T
    Redox Rep; 2024 Dec; 29(1):2345455. PubMed ID: 38723197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The one-carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation.
    Marttila P; Bonagas N; Chalkiadaki C; Stigsdotter H; Schelzig K; Shen J; Farhat CM; Hondema A; Albers J; Wiita E; Rasti A; Warpman Berglund U; Slipicevic A; Mortusewicz O; Helleday T
    Mol Oncol; 2024 Sep; 18(9):2179-2195. PubMed ID: 38533616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of circ-MTHFD2 in diagnosis, pathological staging and prognosis of NSCLC.
    Geng QQ; Wu QF; Zhang Y; Zhang GJ; Fu JK; Chen NZ
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9473-9479. PubMed ID: 33015789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-92a Inhibits Proliferation and Induces Apoptosis by Regulating Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) Expression in Acute Myeloid Leukemia.
    Gu Y; Si J; Xiao X; Tian Y; Yang S
    Oncol Res; 2017 Aug; 25(7):1069-1079. PubMed ID: 28059050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylenetetrahydrofolate dehydrogenase 2 overexpression is associated with tumor aggressiveness and poor prognosis in hepatocellular carcinoma.
    Liu X; Huang Y; Jiang C; Ou H; Guo B; Liao H; Li X; Yang D
    Dig Liver Dis; 2016 Aug; 48(8):953-60. PubMed ID: 27257051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.